Nuevocor: $45 Million Series B Raised For Clinical Development Of Novel Mechanobiology-Centered Therapy For Cardiomyopathy
Summary
Nuevocor, a Singapore-headquartered IND-stage biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, announced the completion of a $45 million Series B financing. Kurma Partners and Angelini Ventures co-led the funding round, which was significantly participated in by existing investors EDBI, ClavystBio, and Boehringer Ingelheim Venture Fund, along with Highlight Capital and SEEDS Capital.LMNA DCM: LMNA DCM is a genetic heart condition caused by mutations in the LMNA gene. Additionally, the company will establish an office in Paris, France, to support clinical development and bring Singapore innovation to patients globally.New board members: Nuevocor also welcomes Amanda Gett-Chaperot, PhD (Kurma Partners) and Elia Stupka, PhD (Angelini Ventures) to its Board of Directors.We are delighted to secure this significant financing milestone to build a global company with such an experienced syndicate of international life science investors. This is an example of how Singapore is bringing transformative innovation to the rest of the world.Nuevocor is providing new hope to a significant population of cardiovascular patients who today lack treatment options by directly targeting the underlying causes of disease. We are proud to support their mission and join the Board, alongside Kurma, ClavystBio, EDBI, Boehringer Ingelheim Venture Fund, and other investors, as the company grows globally, including into Europe.